Department of Epidemiology and Biostatistics, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, United States of America.
Department of Obstetrics and Gynecology and Department of Epidemiology, Columbia University Irving Medical Center, New York, New York, United States of America.
PLoS One. 2022 Jul 28;17(7):e0271038. doi: 10.1371/journal.pone.0271038. eCollection 2022.
Metformin has been suggested to reduce thyroid cancer incidence and to improve thyroid cancer prognosis. We aimed to evaluate the associations between metformin and thyroid cancer incidence and prognosis (metastasis/recurrence/progression-free survival). Cochrane Library, PubMed, ClinicalTrials.gov, and U.S. National Library of Medicine Clinical Trials were searched through the end of December 2021. Data were collected from original observational studies or clinical trials on the incidence or prognosis of thyroid carcinoma outcomes in type 2 diabetes mellitus (T2DM) patients with and without metformin use. Risk of bias in non-randomized studies of interventions (ROBINS-I) tool and Grading of Recommendations, and Assessment, Development and Evaluations (GRADE) approach were used to evaluate the risk of bias and quality of the body of evidence, respectively. In general, 4 studies were related to the thyroid cancer incidence, including 1,705,123 participants metformin users and non-users and yielding a total of 3,238 thyroid cancer events; 3 studies reported the prognosis of thyroid carcinoma based on a total of 4,972 individuals with primary thyroid carcinoma and comorbid type 2 diabetes, and the number of thyroid cancer prognosis cases ranged from 3 to 79. The overall risk of bias of the included studies ranged from moderate to serious. In the random-effects model, the summary relative risk (SRR) for thyroid cancer incidence was 0.743 (95% CI: 0.453-1.220; I2 = 88.7%, low certainty) comparing metformin users to non-users; and SRR for the prognosis of thyroid cancer was 0.504 (95% CI: 0.178-1.430; I2 = 57.5%, low certainty). Non-statistically significant negative associations between metformin use and incidence and prognosis of thyroid cancer were found in the current analysis, although the quantity and quality of the evidence were limited. Futher investigation is needed to evaluate the clinical benefits of metformin on thyroid cancer prevention and treatments.
二甲双胍被认为可以降低甲状腺癌的发病率并改善甲状腺癌的预后。我们旨在评估二甲双胍与甲状腺癌发病率和预后(转移/复发/无进展生存期)的相关性。通过 Cochrane 图书馆、PubMed、ClinicalTrials.gov 和美国国家医学图书馆临床试验检索,截至 2021 年 12 月底。收集了来自观察性研究或临床试验的数据,这些研究涉及使用二甲双胍和不使用二甲双胍的 2 型糖尿病(T2DM)患者的甲状腺癌结局的发病率或预后。使用非随机干预研究的偏倚风险(ROBINS-I)工具和推荐评估、制定与评估(GRADE)方法分别评估偏倚风险和证据质量。一般来说,有 4 项研究与甲状腺癌发病率相关,包括 1705123 名二甲双胍使用者和非使用者,共发生 3238 例甲状腺癌事件;有 3 项研究报告了基于共患 2 型糖尿病的原发性甲状腺癌患者的甲状腺癌预后,甲状腺癌预后病例数为 3 至 79 例。纳入研究的总体偏倚风险为中度至严重。在随机效应模型中,与非使用者相比,二甲双胍使用者的甲状腺癌发病率的汇总相对风险(SRR)为 0.743(95%CI:0.453-1.220;I2 = 88.7%,低确定性);甲状腺癌预后的 SRR 为 0.504(95%CI:0.178-1.430;I2 = 57.5%,低确定性)。当前分析发现,二甲双胍的使用与甲状腺癌的发病率和预后之间存在非统计学显著的负相关,但证据的数量和质量有限。需要进一步研究评估二甲双胍在预防和治疗甲状腺癌方面的临床获益。